Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atara BiotherapeuticsFRA:AT20 +2.94%27 Days Payable is 347.96 as of Jun. 2026, which is 398% above its 10-year median of 69.94. GuruFocus rates FRA:AT20 with a GF Score™ of 27/100 and a GF Value™ of €0.31 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 702 Biotechnology companies, Atara Biotherapeutics ranks better than 79.2% on this metric.
Atara Biotherapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Atara Biotherapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AT20 vs IBIO, ANVS, ENLV: Days Payable Comparison
For the Biotechnology subindustry, Atara Biotherapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atara Biotherapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Atara Biotherapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atara Biotherapeutics (FRA:AT20) has a Days Payable of 347.96 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Atara Biotherapeutics and its competitors. This is 398% above median its historical median of 69.94. Over the past decade, Atara Biotherapeutics' Days Payable has ranged from 38.66 to 501.43. According to the industry distribution chart, Atara Biotherapeutics ranks #146 out of 702 companies in the Biotechnology industry, placing it in the top 20.8%.
Is Atara Biotherapeutics' Days Payable too high?
Atara Biotherapeutics' current Days Payable of 347.96 is 398% above median its 10-year median of 69.94. Over the past 10 years, this metric has ranged from a low of 38.66 to a high of 501.43. The Biotechnology industry median Days Payable is 110.85. Atara Biotherapeutics' value of 347.96 is 213.9% above this industry median. Based on the distribution chart, Atara Biotherapeutics ranks #146 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atara Biotherapeutics has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Days Payable compare to IBIO and ANVS?
According to the Biotechnology industry distribution chart, Atara Biotherapeutics ranks #146 out of 702 companies for Days Payable. This places Atara Biotherapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median Days Payable is 110.85. Atara Biotherapeutics' value of 347.96 is 213.9% above this benchmark. Historically, Atara Biotherapeutics' own Days Payable has ranged from 38.66 to 501.43 over the past decade. While the company's 10-year median is 69.94 vs. the industry median of 110.85, Atara Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.85, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atara Biotherapeutics's current Days Payable of 347.96 is 213.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Atara Biotherapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 110.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atara Biotherapeutics's current Days Payable is 347.96, which is 398% above median its own 10-year median of 69.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (FRA:AT20) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.31, compared to a current price of €7.00 — trading 2158.1% above its estimated fair value. The current Days Payable is 347.96, which is 398% above median its 10-year median of 69.94 and 213.9% above the Biotechnology industry median of 110.85. Atara Biotherapeutics' overall GF Score™ is 27/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Atara Biotherapeutics (FRA:AT20), the current Days Payable is 347.96 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atara Biotherapeutics (FRA:AT20) Overvalued in 2026?
Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued.
The current stock price of €7.00 is trading 2158.1% above its estimated GF Value™ of €0.31.
GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.
Key valuation signals for FRA:AT20:
Days Payable: 347.96 (398% above median its 10-year median of 69.94)
GF Value™: €0.31 vs. price of €7.00 (2158.1% above fair value)
Industry Position: 213.9% above the Biotechnology median (#146 of 702)
No single metric tells the full story. See the FRA:AT20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
27GF Score
Get the complete analysis for FRA:AT20
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AT20 has been successfully added to your 
